Home > Publications database > Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma. > print |
001 | 143730 | ||
005 | 20240229112606.0 | ||
024 | 7 | _ | |a 10.3390/cancers11040584 |2 doi |
024 | 7 | _ | |a pmid:31027243 |2 pmid |
037 | _ | _ | |a DKFZ-2019-01300 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Rong, Chao |b 0 |
245 | _ | _ | |a Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma. |
260 | _ | _ | |a Basel |c 2019 |b MDPI |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1637569427_30857 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) forms a distinct tumor entity with better survival clinical outcome. Numerous underlying molecular mechanisms have been postulated for differences in treatment response, but the impact of MEK/ERK signaling, a main driver of carcinogenesis in various cancers including OPSCC and key player mediating therapy resistance remains elusive. In a retrospective experimental cohort study, primary tumor samples from OPSCC patients (n = 124) were available on tissue microarrays (TMAs) and expression levels of phosphorylated ERK1/2 (pERK1/2) were detected by immunohistochemical staining. Correlations of pERK1/2 expression patterns with clinicopathological features and clinical outcome were evaluated by statistical analysis. A low pERK1/2 expression was strongly associated with HPV-related OPSCC, while primary tumors with high pERK1/2 staining showed a distinctly worse survival outcome and were associated with higher cellular differentiation. Co-activation of both ERK1/2 and AKT was a common event and was associated with unfavorable prognosis in our cohort. However, the combinatorial analysis of pAKT (Ser473) and pERK1/2 did not strengthen the predictive power of pERK1/2, suggesting that pERK1/2 plays a more significant function in OPSCC. In summary, our data provide a compelling experimental and statistical evidence that low levels of tumor cell intrinsic ERK1/2 activation contribute at least in part to the favorable outcome of HPV-related OPSCC. On the other hand, presented findings indicate that non-HPV-related OPSCC with elevated ERK phosphorylation are at high risk for treatment failure and might benefit from targeted therapy of MEK/ERK signaling. |
536 | _ | _ | |a 319H - Addenda (POF3-319H) |0 G:(DE-HGF)POF3-319H |c POF3-319H |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
700 | 1 | _ | |a Muller, Marie |b 1 |
700 | 1 | _ | |a Flechtenmacher, Christa |b 2 |
700 | 1 | _ | |a Holzinger, Dana |0 P:(DE-He78)d84ca2cd7f160904c387ee699735076c |b 3 |u dkfz |
700 | 1 | _ | |a Dyckhoff, Gerhard |b 4 |
700 | 1 | _ | |a Bulut, Olcay Cem |b 5 |
700 | 1 | _ | |a Horn, Dominik |b 6 |
700 | 1 | _ | |a Plinkert, Peter |b 7 |
700 | 1 | _ | |a Hess, Jochen |0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |b 8 |u dkfz |
700 | 1 | _ | |a Affolter, Annette |b 9 |
773 | _ | _ | |a 10.3390/cancers11040584 |g Vol. 11, no. 4, p. 584 - |0 PERI:(DE-600)2527080-1 |n 4 |p 584 |t Cancers |v 11 |y 2019 |x 2072-6694 |
909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:143730 |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)d84ca2cd7f160904c387ee699735076c |
910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-319H |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Addenda |x 0 |
914 | 1 | _ | |y 2019 |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2017 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |
915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2017 |
920 | 1 | _ | |0 I:(DE-He78)F022-20160331 |k F022 |l Infektionen und Krebs-Epidemiologie |x 0 |
920 | 1 | _ | |0 I:(DE-He78)F020-20160331 |k F020 |l Infektionen und Krebs-Epidemiologie |x 1 |
920 | 1 | _ | |0 I:(DE-He78)A102-20160331 |k A102 |l Molekulare Grundlagen von HNO-Tumoren |x 2 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-He78)F022-20160331 |
980 | _ | _ | |a I:(DE-He78)F020-20160331 |
980 | _ | _ | |a I:(DE-He78)A102-20160331 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|